3 Dividend Stocks to Buy in 2026 and Hold Forever

Motley Fool recommends Visa, Novartis and Meta as long-term holdings that combine dividend income with growth potential: Visa (V) offers a 0.8% forward yield and has raised its dividend 379% over the past decade, supported by strong brand and network effects in payments; Novartis (NVS) has increased payouts for 28 consecutive years, a 2.8% forward yield, and a diversified portfolio with more than ten products generating over $1 billion each; Meta (META) initiated a dividend in 2024 (0.3% yield), serves roughly 3.5 billion daily users and is investing heavily in AI to enhance ad targeting and monetization. The write-up underscores modest current yields but robust fundamentals and long-term growth catalysts, framing the picks as attractive for income- and growth-oriented portfolios while reflecting an analyst recommendation rather than new corporate disclosures.

Analysis

Market structure: Payments (V) and large-cap ad-tech (META) are direct beneficiaries of secular shifts—card penetration and digital ads/AI—while defensive pharma (NVS) benefits from demographic-driven demand and dividend stability. Visa's network effects preserve pricing power vs. challengers, but BNPL/crypto rails are credible long-term share-takers if they reach >5-10% penetration in core e‑commerce channels. Strong dividend narratives will attract income-seeking flows if 10‑yr yields stay <4.5%; a sustained rise above that will reprice low-yield tech/dividend stocks faster than pharma.

Risk assessment: Key tail risks are regulatory action (interchange caps or antitrust suits for V; ad-privacy fines or ad-spend downturn for META; patent cliffs or trial failures for NVS) and macro-driven ad cyclicality. Immediate (days) risks: earnings beats/misses and headline regulatory news; short-term (weeks–months): Fed moves and CPI that swing yield-sensitive positioning; long-term (years): secular AI monetization for META and cashless adoption for V. Hidden dependency: merchant acquirers and ad agencies amplify volume elasticity—small ad-dollar or consumer-spend shocks propagate non-linearly.

Trade implications: Favor size into high-moat, cash-generative names but hedge regulatory and rate risk. Use option structures to lever thematic upside (AI for META) while selling premium against long V to enhance yield. Rotate modestly from small-cap cyclicals into NVS as a defensive ballast if volatility rises >25% (VIX threshold) and bond yields fall below 4%.

Contrarian angle: Consensus underestimates Meta’s capital-return signaling—dividend + buybacks could compress reinvestment but materially raise floor valuation; the market may be overpaying for fee stability in payments and underpricing regulatory probability (~15–25% chance of meaningful fee caps over 3 years). Historical parallel: incumbents with network effects (MA/V historically) have survived competitive shocks but lost episodically to regulatory shocks, so position sizing must account for a low‑probability high‑impact downside.

Key Decisions for Investors

• Establish a 2.5% long position in Visa (V) over the next 2–4 weeks; add another 1.5% on any pullback ≥10% from today’s price. Hedge by selling 1–2 month covered calls (~5–7% OTM) to boost yield; trim total exposure by 50% if 10‑yr UST >4.5% for more than 10 trading days.
• Initiate a 3% core position in Novartis (NVS) as defensive income; size to 4–6% if dividend yield sustains ≥3.0% or if a Phase III readout/label expansion is announced. Buy a 6–9 month protective put (~10–15% OTM) ahead of material trial readouts or M&A headlines.
• Express asymmetric upside in Meta (META) with a 2% notional allocation to 12–18 month call spreads (bull call spread) to capture AI-driven ad upside while capping premium; add a further 1–2% if quarterly ad revenue growth re-accelerates above +8% YoY. Exit or convert to stock if total returns exceed +30% within 12 months or if ad-revenue drops YoY for two consecutive quarters.
• Run a relative-value pair: long V (2%) vs short a high-growth payments challenger (e.g., Square SQ, 1.5%) to capture incumbent pricing resilience. Close the pair if V underperforms SQ by >15% over 60 days or if regulatory proposals specifically target interchange fees (reduce pair exposure to zero within 5 trading days).